Ana León

507 total citations
23 papers, 260 citations indexed

About

Ana León is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ana León has authored 23 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 5 papers in Surgery. Recurrent topics in Ana León's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Ana León is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Gastric Cancer Management and Outcomes (7 papers). Ana León collaborates with scholars based in Spain, United States and Ecuador. Ana León's co-authors include Manuel Dómine, Jaime Feliú, Laura García‐Estévez, Víctor Moreno, Cristina Caramés, Federico Rojo, Damián García‐Olmo, Pedro Sánchez‐Rovira, Roberto Sosa Hernández and J. I. Martı́n and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Ana León

21 papers receiving 259 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ana León Spain	9	196	101	72	70	45	23	260
Ming-Ming He China	9	149 0.8×	76 0.8×	64 0.9×	86 1.2×	77 1.7×	11	256
Rosario Dueñas Spain	10	302 1.5×	136 1.3×	48 0.7×	102 1.5×	29 0.6×	19	359
Daisuke Ujiie Japan	9	172 0.9×	75 0.7×	129 1.8×	56 0.8×	63 1.4×	18	318
Laia Bernet Spain	9	123 0.6×	127 1.3×	38 0.5×	48 0.7×	57 1.3×	25	229
Georgia Milaki Greece	10	186 0.9×	136 1.3×	135 1.9×	99 1.4×	34 0.8×	15	317
Katsuhiko Nakatsukasa Japan	12	155 0.8×	85 0.8×	47 0.7×	36 0.5×	68 1.5×	36	264
Sofía del Carmen Spain	9	121 0.6×	86 0.9×	87 1.2×	55 0.8×	60 1.3×	23	248
Dario Nicolella Italy	9	227 1.2×	45 0.4×	108 1.5×	158 2.3×	17 0.4×	16	332
Krisida Cerma Italy	6	137 0.7×	47 0.5×	74 1.0×	64 0.9×	19 0.4×	9	214
T.W. Kim South Korea	8	226 1.2×	38 0.4×	32 0.4×	93 1.3×	76 1.7×	26	264

Countries citing papers authored by Ana León

Since Specialization

Citations

This map shows the geographic impact of Ana León's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana León with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana León more than expected).

Fields of papers citing papers by Ana León

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana León. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana León. The network helps show where Ana León may publish in the future.

Co-authorship network of co-authors of Ana León

This figure shows the co-authorship network connecting the top 25 collaborators of Ana León. A scholar is included among the top collaborators of Ana León based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana León. Ana León is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

León, Ana, et al.. (2024). Cirrosis Hepática en Paciente Masculino de 15 Años Reporte de Caso. Ciencia Latina Revista Científica Multidisciplinar. 8(1). 1079–1090.

Franco, Fernando, Juan Carlos Cámara, Ana López‐Alfonso, et al.. (2020). Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical & Translational Oncology. 23(4). 812–819. 11 indexed citations

Feliú, Jaime, Rocio García‐Carbonero, Jaume Capdevila, et al.. (2019). VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02). Cancer Medicine. 9(3). 1008–1016. 8 indexed citations

Franco, Fernando, et al.. (2018). Clinical outcomes of FOLFIRINOX and gemcitabine/nab-paclitaxel in the real world setting.. Journal of Clinical Oncology. 36(4_suppl). 440–440. 2 indexed citations

Caramés, Cristina, Ion Cristóbal, Pablo Mínguez, et al.. (2016). MicroRNA-31 overexpression is able to predict pathological response and outcome in locally advanced rectal cancer. Annals of Oncology. 27. vi179–vi179. 1 indexed citations

López‐Ríos, Fernando, Carolina Domínguez, Paula Jiménez Fonseca, et al.. (2016). PI3K upregulation as a negative predictive factor of survival in HER2 amplified gastric cancer treated with Trastuzumab.. Journal of Clinical Oncology. 34(15_suppl). e15567–e15567. 2 indexed citations

Llovet, Patricia, Javier Sastre, Julián Sanz‐Ortega, et al.. (2015). Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Molecular Diagnosis & Therapy. 19(6). 397–408. 22 indexed citations

Caramés, Cristina, Ion Cristóbal, Víctor Moreno, et al.. (2015). MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer. International Journal of Colorectal Disease. 30(7). 899–906. 40 indexed citations

Izarzugaza, Yann, Manuel Dómine, Federico Rojo, et al.. (2012). Prevalence of EGFR mutations in non-small cell lung cancer (NSCLC) smoker patients.. Journal of Clinical Oncology. 30(15_suppl). e21015–e21015. 1 indexed citations

10.

Dómine, Manuel, Yann Izarzugaza, Federico Rojo, et al.. (2012). KRAS mutations as predictive biomarker in patients with EGFR wild-type stage IV nonsquamous non-small cell lung cancer (NSCLC) recruited in a phase II clinical study with carboplatin-docetaxel-bevacizumab.. Journal of Clinical Oncology. 30(15_suppl). e18069–e18069. 1 indexed citations

11.

Zazo, Sandra, Juan Madoz‐Gúrpide, Manuel Dómine, et al.. (2012). Role of c-MET pathway in the outcome prediction of cetuximab-based therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.. Journal of Clinical Oncology. 30(15_suppl). 5520–5520. 2 indexed citations

12.

Zazo, Sandra, Cristina Caramés, Gloria Serrano, et al.. (2012). Prognostic Role of Kras Mutations Detected by High-Sensitivity Taqmelt PCR Assay in Metastatic Colorectal Cancer. Annals of Oncology. 23. ix187–ix187.

13.

Feliú, Jaime, Pablo Borrega, Ana León, et al.. (2010). Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 67(1). 215–221. 26 indexed citations

14.

García‐Estévez, Laura, Norberto Batista, Pedro Sánchez‐Rovira, et al.. (2008). A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes. Clinical Breast Cancer. 8(2). 149–154. 30 indexed citations

15.

Sánchez‐Rovira, Pedro, Manuel Dómine, Ana León, et al.. (2007). Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study. Clinical & Translational Oncology. 9(5). 317–322. 6 indexed citations

16.

Feliú, Jaime, Miguel Cruz, M. Lomas, et al.. (2006). Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. Cancer Chemotherapy and Pharmacology. 58(4). 419–426. 4 indexed citations

17.

García‐Estévez, Laura, Pedro Sánchez‐Rovira, Manuel Dómine, et al.. (2004). Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: Preliminary results of a phase II and pharmacogenomic study. Seminars in Oncology. 31(2 Suppl 5). 31–36. 8 indexed citations

18.

Virizuela, Juan Antonio, Jesús Florián, M. Lomas, et al.. (2003). Gemcitabine/Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines: Results of a Phase II Trial. Clinical Breast Cancer. 4(1). 46–50. 14 indexed citations

19.

Dómine, Manuel, Laura García‐Estévez, Ana León, et al.. (2001). Gemcitabine and Carboplatin for Patients With Advanced Non-Small Cell Lung Cancer. Seminars in Oncology. 28(3 Suppl 10). 4–9. 9 indexed citations

20.

Dómine, Manuel, et al.. (2000). Carboplatin (C) and Gemcitabine (G) in advanced non small cell lung cancer (NSCLC): An effective and well tolerated regimen. Lung Cancer. 29(1). 85–85. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact